Analysis of C-Peptide Levels Among Gynaecological Malignancies Patients Underwent Chemotherapy with Carboplatin Regiment
DOI:
https://doi.org/10.24293/ijcpml.v29i1.1967Keywords:
Carboplatin, C-peptide, gynaecological malignanciesAbstract
C-peptide is part of the, which its amounts were equal to endogenous insulin secreted by pancreatic β cells. Carboplatin is one of the chemotherapy regimens that are widely used to treat gynecological malignancies. Carboplatin may cause the damage of β-islets of Langerhans, which may cause defects in insulin synthesis leading to secondary diabetes mellitus or other types of diabetes mellitus. The purpose of this study was to determine the differences in C-peptide, (which reflects endogenous insulin levels) levels in patients with gynecologic malignancy who underwent carboplatin chemotherapy. This study was a comparative observational study with a cross-sectional design. There was a total of 42 subjects who met the inclusion criteria. Subjects with gynecological malignancy post-carboplatin chemotherapy regimens had lower serum C-peptide levels in group II compared to group I. Serum C-peptide levels can further be used to monitor side effects of carboplatin and can be used as a test to diagnose the other types of diabetes mellitus especially before starting the fourth cycle
Downloads
References
Mayor S. WHO priority list of medical devices for cancer management. Lancet Oncol, 2017; 18(7): 856.
Data Rekam Medik Rumah Sakit Dr. Hasan Sadikin Bandung. 2019 (unpublished).
Whitridge WJ, Gary CF, Leveno KJ, Bloom SL, Spong CY, et al. Williams obstetrics, 24e. Implantation and placental development. New York, N.Y, McGraw Hill Medical, 2016; 80-110.
Aronson JK, Dukes MNG. Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions.15e. Amsterdam, Boston, Elsevier, 2015; 95-8.
Collins IM, Roberts-Thomson R, Faulkner D, Rischin D, Friedlander M, Mileshkin L. Carboplatin dosing in ovarian cancer: Problems and pitfalls. Int J Gynecol Cancer, 2015; 21(7): 1213-8.
Nan DN, Fernandez-Ayala M, Vega Villegas ME, Garcia-Castano A, Rivera F, et al. Diabetes mellitus following cisplatin treatment. Acta Oncol, 2016; 42(1): 75-8.
Pandey V, Chaube B, Bhat MK. Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells. J Cell Biochem, 2015; 112(10): 2942-52.
Shulman GI. Cellular mechanisms of insulin resistance, perspective series. J Clin Invest, 2016; 106(2): 171-6.
Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature, Insight Review Articles, 2015; 414(6865): 799-806.
Rubinstein M, Halpenny D, Makker V, Grisham RN, Aghajanian C, Cadoo K. Retreatment with carboplatin and paclitaxel for reccurent endometrial cancer: Aretrospective study of the memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep, 2019; 28: 120-123.
Mariyam SB, Muthubeevi SB, Vasantha SC. Serum C-peptide level in obese and non-obese patients with type 2 diabetes mellitus. J Evolution Med Dent, 2017; 6(5): 350-3.
Ahmed F, Ali MJ, Kondapi AK. Carboplatin loades protein nanoparticles exhibit improve anti-proliferative activity in retinoblastoma cells. International J of Biological Macromolecules, 2016; 577-82.
Karanam V, Marslin G, Krishnamoorthy B, Chellan V, Siram K, et al. Poly caprolactone nanoparticles of carboplatin: Preparation, characterization and in-vitro cytotoxicity evaluation in U-87 MG cell lines. Colloids and Surface B, Biointerfaces, 2015; 48-52.
Wheate NJ, Walker S, Craig GE, Oun R. Thes status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Transactions, 2016; 8057-8340.
Collins IM, Thomson RR, Faulkner D, Rischin D, Friedlander M, Mileshkin L. Carboplatin dosing in ovarian cancer. International J of Gynecological Cancer, 2016; 21: 1213-8.
Aldossary SA. Review on pharmacology of cisplatin: Clinical use, toxicity, and mechanism of resistance of cisplatin. Biomed & Pharmacol J, 2018; 12(1): 7-15.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
